Patients with nonvalvular atrial fibrillation after PCI
Conditions
Interventions
Sponsors
Fujian Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years at the time of screening, regardless of gender; 2. Patients with non-valvular atrial fibrillation, patients with ischemia risk assessment CHA2DS2-VASc score >= 2 points and bleeding risk assessment HAS-BLED score >= 2 points; 3. Patients diagnosed with coronary atherosclerotic heart disease and undergoing elective PCI; 4. Patients with successful PCI; 5. Those who are willing to participate in this study and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. The total number of stents placed > 3; 2. Patients with severe diseases, life expectancy = 180mmHg or diastolic blood pressure >= 110mmHg) after drug treatment; patients with co-infections, immune system diseases, and malignant tumors; 5. Those who have any of the following conditions: cardiogenic shock, chronic congestive heart failure NYHA grade >= grade III or echocardiographic measurement of left ventricular ejection fraction < 35%, hypotension (systolic blood pressure < 90mmHg and or diastolic blood pressure < 60mmHg), severe arrhythmia (including high-grade atrioventricular block, sick sinus syndrome, persistent ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, liver insufficiency (non-heart disease causes ALT or AST exceeds 3 times the upper limit of normal), severe renal insufficiency (eGFR < 30ml/min), liver cirrhosis; 6. Patients with high risk of ischemia, including left main artery disease, multivessel disease, bifurcation disease, and calcification disease; 7. Plan to undergo other surgical operations within 1 month after participating in this trial; 8. Have a history of severe allergies, non-allergic drug reactions, or allergies to 2 or more drugs (including contrast agents), or known to be allergic to drugs similar to the study drug (clopidogrel, rivaroxaban) or Those who are contraindicated to use aspirin; 9. Pregnant and lactating women; 10. Other matters deemed unsuitable by the researcher to participate in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of Life Scale Concise Health Status Questionnaire SF-36;Seattle Angina Questionnaire (SAQ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment of severe or non-serious clinically related major bleeding (ISTH) or clinically related non-major bleeding events for 1, 3, and 6 months; | — |
Countries
China
Contacts
Public ContactChen Hui
Fujian Provincial Hospital
Outcome results
None listed